When it comes to cancer drug deals, one hot protein family is raking in billions: report
admin 21st August 2019 Uncategorised 0Drugs that inhibit cancer-causing proteins known as kinases have driven nearly $100 billion in deals since 2010, SVB Leerink finds. And the analysts figure that drug class—and its propensity to drive acquisitions—will only grow, thanks to speedy FDA reviews, strong pricing trends and next-gen entrants.
More: When it comes to cancer drug deals, one hot protein family is raking in billions: report
Source: fierce